J Virol. 1987 June; 61(6): 1851-1854
Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats.
G A Prince,
V G Hemming,
R L Horswood,
P A Baron and
R M Chanock
ABSTRACT
Initial studies of the prophylactic effect of parenterally administered respiratory syncytial virus (RSV)-neutralizing antibodies in cotton rats indicated that virus replication in lung tissues was restricted when animals with preexisting antibody titers in serum of 1:100 or more (as measured by plaque reduction) were challenged intranasally with 10(4) PFU of virus. Subsequently, a therapeutic effect of parenterally administered RSV antibodies (present in human gamma globulin) was demonstrated in both cotton rats and owl monkeys. Parenteral inoculation of RSV-infected cotton rats or owl monkeys with purified human immunoglobulin licensed for intravenous administration in humans (IVIG) effected a 10(-1.7) to 10(-2.7) reduction in the level of pulmonary virus at the height of infection. Because of these encouraging results, we examined topical administration of IVIG to determine whether it was also effective and whether it offered an advantage over the parenteral route with regard to simplicity and the dose required for full therapeutic effect. IVIG (0.025 g/kg) administered topically by the intranasal route to anesthetized cotton rats at the height of RSV infection effected a 10(2.2)-fold reduction in viral titers of pulmonary tissues and a complete clearance of detectable virus in 92% of the animals within 24 h. In contrast, 4 g of IVIG per kg was required to produce a comparable therapeutic effect when the material was administered parenterally. Thus, the therapeutic effect of IVIG was 160 times greater by the topical route than by parenteral inoculation.
J Virol. 1987 June; 61(6): 1851-1854
This article has been cited by other articles:
-
Collins, P. L., Graham, B. S.
(2008). Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis. J. Virol.
82: 2040-2055
[Full Text]
-
Boukhvalova, M. S., Prince, G. A., Blanco, J. C. G.
(2007). Respiratory Syncytial Virus Infects and Abortively Replicates in the Lungs in Spite of Preexisting Immunity. J. Virol.
81: 9443-9450
[Abstract]
[Full Text]
-
Singleton, R., Etchart, N., Hou, S., Hyland, L.
(2003). Inability To Evoke a Long-Lasting Protective Immune Response to Respiratory Syncytial Virus Infection in Mice Correlates with Ineffective Nasal Antibody Responses. J. Virol.
77: 11303-11311
[Abstract]
[Full Text]
-
Mozdzanowska, K., Feng, J., Gerhard, W.
(2003). Virus-Neutralizing Activity Mediated by the Fab Fragment of a Hemagglutinin-Specific Antibody Is Sufficient for the Resolution of Influenza Virus Infection in SCID Mice. J. Virol.
77: 8322-8328
[Abstract]
[Full Text]
-
Viuff, B., Tjornehoj, K., Larsen, L. E., Rontved, C. M., Uttenthal, A., Ronsholt, L., Alexandersen, S.
(2002). Replication and Clearance of Respiratory Syncytial Virus: Apoptosis Is an Important Pathway of Virus Clearance after Experimental Infection with Bovine Respiratory Syncytial Virus. Am. J. Pathol.
161: 2195-2207
[Abstract]
[Full Text]
-
Zhang, L., Peeples, M. E., Boucher, R. C., Collins, P. L., Pickles, R. J.
(2002). Respiratory Syncytial Virus Infection of Human Airway Epithelial Cells Is Polarized, Specific to Ciliated Cells, and without Obvious Cytopathology. J. Virol.
76: 5654-5666
[Abstract]
[Full Text]
-
Prince, G. A., Ottolini, M. G., Moscona, A.
(2001). Contribution of the Human Parainfluenza Virus Type 3 HN-Receptor Interaction to Pathogenesis In Vivo. J. Virol.
75: 12446-12451
[Abstract]
[Full Text]
-
Crowe, J. E. Jr., Firestone, C.-Y., Murphy, B. R.
(2001). Passively Acquired Antibodies Suppress Humoral But Not Cell-Mediated Immunity in Mice Immunized with Live Attenuated Respiratory Syncytial Virus Vaccines. J. Immunol.
167: 3910-3918
[Abstract]
[Full Text]
-
Masot, A. J., Kelling, C. L., Lopez, O., Sur, J. H., Redondo, E.
(2000). In Situ Hybridization Detection of Bovine Respiratory Syncytial Virus in the Lung of Experimentally Infected Lambs. Vet Pathol
37: 618-625
[Abstract]
[Full Text]
-
Weltzin, R., Monath, T. P.
(1999). Intranasal Antibody Prophylaxis for Protection against Viral Disease. Clin. Microbiol. Rev.
12: 383-393
[Abstract]
[Full Text]
-
Bourgeois, C., Bour, J. B., Aho, L. S., Pothier, P.
(1998). Prophylactic Administration of a Complementarity-Determining Region Derived from a Neutralizing Monoclonal Antibody Is Effective against Respiratory Syncytial Virus Infection in BALB/c Mice. J. Virol.
72: 807-810
[Abstract]
[Full Text]
-
Groothuis, J. R., Simoes, E., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. J., Arrobio, J., Meissner, H. C., Fulton, D. R., Welliver, R. C., Tristram, D. A., Siber, G. R., Prince, G. A., Van Raden, M., Hemming, V. G., The Respiratory Syncytial Virus Immune Globulin St,
(1993). Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children. NEJM
329: 1524-1530
[Abstract]
[Full Text]
-
McIntosh, K.
(1993). Respiratory Syncytial Virus -- Successful Immunoprophylaxis at Last. NEJM
329: 1572-1574
[Full Text]
Copyright © 1987 by the American Society for Microbiology. All rights reserved.